search
Back to results

tDCS Effect on Cognitive Functions From Patients With Alzheimer's Disease or Progressive Primary Aphasia (ALSTICO)

Primary Purpose

Alzheimer's Disease, Progressive Primary Aphasia, Early or Mild State

Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
transcranial Direct Current Stimulation (tDCS)
Sponsored by
Centre Hospitalier Universitaire de Besancon
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alzheimer's Disease

Eligibility Criteria

60 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRADA) criteria (Alzheimer's patient) OR Gordo-Tempini criteria (PPA's patient)
  • CDR score ≤ 2
  • treatment by IAChE ≥ 3 months
  • MADRS score < 18
  • w/o severe progressive somatic pathology (especially tumor diseases)

Exclusion Criteria:

  • last neuropsychological assessment < 6 months
  • presence of a specific contraindication for tDCS (e.g. personal history of epilepsy, metallic head implant, cardiac pacemaker)

Sites / Locations

  • CHU Besancon - Clinical Psychiatric DepartmentRecruiting
  • Hopital Universitaire Dijon
  • Assistance Publique - Hôpitaux ParisRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Sham Comparator

Arm Label

anodal tDCS on left DLPFC (F3)

sham tDCS on left DLPFC (F3)

Arm Description

tDCS is a non-invasive neuromodulation method, which delivers a constant current of low intensity (1 mA) during 30 minutes for 10 sessions. Anode is placed on the scalp facing on left DLPFC (F3) and cathode between Fp2-F8 EEG-repair.

Sham tDCS differs from active tDCS by the interruption of stimulation after 15 sec and reactivation of the stimulation 15 sec before the end of the session (30 minutes - 10 sessions. Anode is placed on the scalp facing on left DLPFC (F3) and cathode between Fp2-F8 EEG-repair.

Outcomes

Primary Outcome Measures

change from baseline cognitive functions at 3 weeks
neuropsychological assessments include Rapid battery tests (Bereay et al., 2015)

Secondary Outcome Measures

Full Information

First Posted
August 11, 2016
Last Updated
October 12, 2017
Sponsor
Centre Hospitalier Universitaire de Besancon
Collaborators
Centre Hospitalier Universitaire Dijon, Assistance Publique - Hôpitaux de Paris
search

1. Study Identification

Unique Protocol Identification Number
NCT02873546
Brief Title
tDCS Effect on Cognitive Functions From Patients With Alzheimer's Disease or Progressive Primary Aphasia
Acronym
ALSTICO
Official Title
Evaluation de l'Effet de la tDCS Sur Les Fonctions Cognitives de Patients Souffrant de Maladie d'Alzheimer et Maladies apparentées au Stade léger
Study Type
Interventional

2. Study Status

Record Verification Date
October 2017
Overall Recruitment Status
Unknown status
Study Start Date
July 19, 2013 (Actual)
Primary Completion Date
January 31, 2018 (Anticipated)
Study Completion Date
July 31, 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire de Besancon
Collaborators
Centre Hospitalier Universitaire Dijon, Assistance Publique - Hôpitaux de Paris

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the effect of 10 sessions of anodal transcranial Direct Current Stimulation (tDCS - 1 mA) applied to left Cortex DorsoLateral PreFrontal (CDLPF) of Alzheimer's or Primary Progressive Aphasia (PPA) patients compared to the application of a placebo tDCS (sham procedure) on cognitive functions, which are evaluated at short term (1 week post-treatment) and mild term (3 weeks post-treatment). After unblinding, patients who received placebo treatment could be received active tDCS.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer's Disease, Progressive Primary Aphasia, Early or Mild State

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
52 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
anodal tDCS on left DLPFC (F3)
Arm Type
Active Comparator
Arm Description
tDCS is a non-invasive neuromodulation method, which delivers a constant current of low intensity (1 mA) during 30 minutes for 10 sessions. Anode is placed on the scalp facing on left DLPFC (F3) and cathode between Fp2-F8 EEG-repair.
Arm Title
sham tDCS on left DLPFC (F3)
Arm Type
Sham Comparator
Arm Description
Sham tDCS differs from active tDCS by the interruption of stimulation after 15 sec and reactivation of the stimulation 15 sec before the end of the session (30 minutes - 10 sessions. Anode is placed on the scalp facing on left DLPFC (F3) and cathode between Fp2-F8 EEG-repair.
Intervention Type
Device
Intervention Name(s)
transcranial Direct Current Stimulation (tDCS)
Other Intervention Name(s)
EldithDC-NeuroConn Stimulator (NeuroConn Gmbh, Germany)
Intervention Description
After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 2 session per day during 5 consecutive days. Subjects will be monitored during tDCS sessions for any side effects or adverse events.
Primary Outcome Measure Information:
Title
change from baseline cognitive functions at 3 weeks
Description
neuropsychological assessments include Rapid battery tests (Bereay et al., 2015)
Time Frame
baseline, day 5 and 3 weeks post-tDCS

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRADA) criteria (Alzheimer's patient) OR Gordo-Tempini criteria (PPA's patient) CDR score ≤ 2 treatment by IAChE ≥ 3 months MADRS score < 18 w/o severe progressive somatic pathology (especially tumor diseases) Exclusion Criteria: last neuropsychological assessment < 6 months presence of a specific contraindication for tDCS (e.g. personal history of epilepsy, metallic head implant, cardiac pacemaker)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Pierre Vandel, MD PhD
Phone
+33381219007
Email
pierre.vandel@univ-fcomte.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Magali Nicolier, PhD
Phone
+33381219007
Email
mnicolier@chu-besancon.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Claire Paquet, MD PhD
Organizational Affiliation
Assitance Publique - Hôpitaux Paris
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Bernard Bonnin, MD PhD
Organizational Affiliation
Centre Hospitalier Universaitaire Dijon
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU Besancon - Clinical Psychiatric Department
City
Besancon
ZIP/Postal Code
25000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Magali Nicolier, PhD
Phone
+33381219007
Email
mnicolier@chu-besancon.fr
First Name & Middle Initial & Last Name & Degree
Pierre Vandel, MD PhD
First Name & Middle Initial & Last Name & Degree
Eloi Magnin, MD PhD
Facility Name
Hopital Universitaire Dijon
City
Dijon
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bernard Bonnin, MD PhD
First Name & Middle Initial & Last Name & Degree
Bernard Bonnin, MD PhD
First Name & Middle Initial & Last Name & Degree
Trojak Benoît, MD PhD
Facility Name
Assistance Publique - Hôpitaux Paris
City
Paris
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hélène Francisque
Phone
+33140054390
Email
helene.francisque@gmail.com
First Name & Middle Initial & Last Name & Degree
Hélène Francisque
First Name & Middle Initial & Last Name & Degree
Claire Paquet, MD PhD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
26212200
Citation
Bereau M, Sylvestre G, Mauny F, Puyraveau M, Baudier F, Magnin E, Berger E, Vandel P, Galmiche J, Chopard G. [Assessment of 10 years of memory consultations in the Franche-Comte: Description and analysis of the RAPID regional database]. Rev Neurol (Paris). 2015 Sep;171(8-9):655-61. doi: 10.1016/j.neurol.2015.04.008. Epub 2015 Jul 23. French.
Results Reference
background

Learn more about this trial

tDCS Effect on Cognitive Functions From Patients With Alzheimer's Disease or Progressive Primary Aphasia

We'll reach out to this number within 24 hrs